Bavarian Nordic — August 2024
-
Revenue for the year furthermore comprises approximately DKK 2,100 million from Travel Health vaccines and approximately DKK 200 million from contract work, thus totaling an expected DKK 5,000-5,300 million. The EBITDA is expected to reach DKK 1,100-1,350 million.
All full year revenue and earnings estimates mentioned are in line with previous guidance.
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1197067/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
...vi må åbne et stykke over 200
-
..shorternes sidste bastion er pist væk
-
..rolig kkjoel, de er allerede væk
-
..enig @theNote - og da lidt sjovt jeg netop skrev om den råvaccineordre, der formodentlig næsten ville lukke hullet i prognosen...igår.
-
Mpox udvikler sig stadig, og selv om det er dejligt at se en ordre, er det stadig Mpox og en mulig PHEIC (Public Health Emergency og Inernational Concern) der virkelig vil rykke kursen op.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind